Login to Your Account



Novartis, Cell Genesys Enter $28.5M Oncolytic Virus Deal

By Randall Osborne


Thursday, July 24, 2003
About five months after curtailing its gene therapy efforts in favor of other programs, Cell Genesys Inc.'s move has paid off in the form of a $28.5 million deal with Novartis AG to develop oncolytic virus products. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription